Library · Heart, blood & kidney · Treatment of acute decompensated heart failure
Nesiritide
BNP, Brain natriuretic peptide, Natrecor
A recombinant version of human B-type natriuretic peptide, FDA-approved in 2001 for acute decompensated heart failure. It causes vasodilation, natriuresis, and diuresis while damping the renin-angiotensin-aldosterone system; kidney and mortality concerns later narrowed its use to select, volume-overloaded patients.
Research score 80/100. Reference only, not a dose.
Boxed warning: Risk of major cardiovascular events
- Cardiovascular Health
- Blood Pressure Regulation
- Cardioprotection
- Anti-inflammatory
- Inflammation Resolution
- US status
- FDA Approved
- Approval
- FDA Approved
- Evidence
- FDA approved for acute decompensated heart failure. Improves hemodynamics (reduces PCWP).
- Research score
- 80 / 100
- Indication
- Heart Failure
- Origin
- USA
- Source category
- Heart & Cardiovascular
- Status group
- Approved / prescription
Mechanism
Binds natriuretic peptide receptor-A, raising cGMP and activating protein kinase G to relax vascular smooth muscle, lowering preload and afterload, increasing natriuresis, and suppressing the renin-angiotensin-aldosterone system.
Safety file
Hypotension is the main dose-limiting risk; kidney function needs monitoring; headache and nausea are common.
- Hypotension
- Kidney dysfunction
- Dizziness
- Headache
- Nausea